Publicaciones en colaboración con investigadores/as de Carl von Ossietzky University of Oldenburg (4)

2022

  1. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study

    Clinical Lung Cancer, Vol. 23, Núm. 8, pp. 720-730

2021

  1. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    Journal of Thoracic Oncology, Vol. 16, Núm. 12, pp. 2091-2108

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

2018

  1. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

    New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039